Immunosuppressive/anti-inflammatory cytokines directly and indirectly inhibit endothelial dysfunction-A novel mechanism for maintaining vascular function

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Shao, Ying ^a   Cheng, Zhongjian ^a   Li, Xinyuan ^a   Chernaya, Valeria ^a   Wang, Hong ^a   Yang, Xiao Feng ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti inflammatory cytokines; Endothelial dysfunction; Metabolic cardiovascular diseases

Indexed keywords

ANGIOTENSIN II; CYTOKINE; ENDOTHELIN 1; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; INTERLEUKIN 10; INTERLEUKIN 35; MICRORNA; NITRIC OXIDE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DISEASE CONTROL; DISEASE COURSE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT; VASCULAR ENDOTHELIUM; VASCULITIS; VASOCONSTRICTION; VASODILATATION; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNE TOLERANCE; INFLAMMATION;

EID: 84920841994     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0080-6     Document Type: Review

References (184)

1. Aird WC: Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012, 2(1):a006429.
2. Aird WC: Endothelium as an organ system. Crit Care Med 2004, 32(5 Suppl):S271-S279.
3. Jaffe EA: Cell biology of endothelial cells. Hum Pathol 1987, 18(3):234-239.
4. Mai J, Virtue A, Shen J, Wang H, Yang XF: An evolving new paradigm: Endothelial cells-conditional innate immune cells. J Hematol Oncol 2013, 6:61.
5. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ, Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension: Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005, 23(1):7-17.
6. Yang XF, Yin Y, Wang H: Vascular inflammation and atherogenesis are activated via receptors for pamps and suppressed by regulatory t cells. Drug Discov Today Ther Strateg 2008, 5(2):125-142.
7. Boisrame-Helms J, Kremer H, Schini-Kerth V, Meziani F: Endothelial dysfunction in sepsis. Curr Vasc Pharmacol 2013, 11(2):150-160.
8. Hansell C, Nibbs R: Professional and part-Time chemokine decoys in the resolution of inflammation. Sci STKE 2007, 2007(384):e18.
9. Trayhurn P, Wood IS: Signalling role of adipose tissue: Adipokines and inflammation in obesity. Biochem Soc Trans 2005, 33(Pt 5):1078-1081.
10. Pedersen BK, Febbraio MA: Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 2012, 8(8):457-465.
11. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL: Oxidation-specific epitopes are danger-Associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011, 108(2):235-248.
12. Jialal I, Kaur H, Devaraj S: Toll-like receptor status in obesity and metabolic syndrome: A translational perspective. J Clin Endocrinol Metab 2014, 99(1):39-48.
13. Lackie JM: A Dictionary of Biomedicine. 1st edition. Oxford: Oxford University Press; 2010.
14. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991, 88(5):1747-1754.
15. Kasai T, Inada K, Takakuwa T, Yamada Y, Inoue Y, Shimamura T, Taniguchi S, Sato S, Wakabayashi G, Endo S: Anti-inflammatory cytokine levels in patients with septic shock. Res Commun Mol Pathol Pharmacol 1997, 98(1):34-42.
16. Murdaca G, Spano F, Cagnati P, Puppo F: Free radicals and endothelial dysfunction: potential positive effects of TNF-Alpha inhibitors. Redox Rep 2013, 18(3):95-99.
17. Kusuhara M, Isoda K, Ohsuzu F: Interleukin-1 and occlusive arterial diseases. Cardiovasc Hematol Agents Med Chem 2006, 4(3):229-235.
18. Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR: Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013, 62(11):1543-1552.
19. Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction: Testing and clinical relevance. Circulation 2007, 115(10):1285-1295.
20. Pober JS, Sessa WC: Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007, 7(10):803-815.
21. Bautista LE: Inflammation, endothelial dysfunction, and the risk of high blood pressure: Epidemiologic and biological evidence. J Hum Hypertens 2003, 17(4):223-230.
22. Hadi HA, Carr CS, Al Suwaidi J: Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005, 1(3):183-198.
23. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S: Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm 2010, 2010:792393.
24. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000, 87(10):840-844.
25. Cai H: Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res 2005, 68(1):26-36.
26. Xu J, Zou MH: Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 2009, 120(13):1266-1286.
27. Sprague AH, Khalil RA: Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009, 78(6):539-552.
28. Frangogiannis NG: Regulation of the inflammatory response in cardiac repair. Circ Res 2012, 110(1):159-173.
29. Banchereau J, Pascual V, O'Garra A: From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012, 13(10):925-931.
30. Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, Tramontana S, Perticone F, Naccarato P, Camici P, Picano E, Cortigiani L, Bevilacqua M, Milazzo L, Cusi D, Barlassina C, Sarzi-Puttini P, Turiel M: From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010, 9(12):830-834.
31. Stoner L, Sabatier MJ: Use of ultrasound for non-invasive assessment of flow-mediated dilation. J Atheroscler Thromb 2012, 19(5):407-421.
32. Roustit M, Cracowski JL: Assessment of endothelial and neurovascular function in human skin microcirculation. Trends Pharmacol Sci 2013, 34(7):373-384.
33. Mulvany MJ, Halpern W: Mechanical properties of vascular smooth muscle cells in situ. Nature 1976, 260(5552):617-619.
34. Spiers A, Padmanabhan N: A guide to wire myography. Methods Mol Med 2005, 108:91-104.
35. Shahid M, Buys ES: Assessing murine resistance artery function using pressure myography. J Vis Exp 2013, (76):e50328.
36. Bridges LE, Williams CL, Pointer MA, Awumey EM: Mesenteric artery contraction and relaxation studies using automated wire myography. J Vis Exp 2011, (55):e3119.
37. Mulvany MJ, Aalkjaer C: Structure and function of small arteries. Physiol Rev 1990, 70(4):921-961.
38. Lei C, Yu B, Shahid M, Beloiartsev A, Bloch KD, Zapol WM: Inhaled nitric oxide attenuates the adverse effects of transfusing stored syngeneic erythrocytes in mice with endothelial dysfunction after hemorrhagic shock. Anesthesiology 2012, 117(6):1190-1202.
39. Cheng Z, Jiang X, Kruger WD, Pratico D, Gupta S, Mallilankaraman K, Madesh M, Schafer AI, Durante W, Yang X, Wang H: Hyperhomocysteinemia impairs endothelium-derived hyperpolarizing factor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice. Blood 2011, 118(7):1998-2006.
40. Gutierrez E, Flammer AJ, Lerman LO, Elizaga J, Lerman A, Fernandez-Aviles F: Endothelial dysfunction over the course of coronary artery disease. Eur Heart J 2013, 34(41):3175-3181.
41. Cheng Z, Yang X, Wang H: Hyperhomocysteinemia and endothelial dysfunction. Curr Hypertens Rev 2009, 5(2):158-165.
42. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87(1):315-424.
43. Rafikov R, Fonseca FV, Kumar S, Pardo D, Darragh C, Elms S, Fulton D, Black SM: ENOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 2011, 210(3):271-284.
44. Kashiwagi S, Atochin DN, Li Q, Schleicher M, Pong T, Sessa WC, Huang PL: ENOS phosphorylation on serine 1176 affects insulin sensitivity and adiposity. Biochem Biophys Res Commun 2013, 431(2):284-290.
45. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399(6736):601-605.
46. Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R: Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. Circ Res 2001, 88(11):E68-E75.
47. Olson SC, Dowds TA, Pino PA, Barry MT, Burke-Wolin T: ANG II stimulates endothelial nitric oxide synthase expression in bovine pulmonary artery endothelium. Am J Physiol 1997, 273(2 Pt 1):L315-L321.
48. Marasciulo FL, Montagnani M, Potenza MA: Endothelin-1: The yin and yang on vascular function. Curr Med Chem 2006, 13(14):1655-1665.
49. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P: Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci U S A 1993, 90(15):7240-7244.
50. Andrew PJ, Mayer B: Enzymatic function of nitric oxide synthases. Cardiovasc Res 1999, 43(3):521-531.
51. Anselm E, Chataigneau M, Ndiaye M, Chataigneau T, Schini-Kerth VB: Grape juice causes endothelium-dependent relaxation via a redox-sensitive Src-And Akt-dependent activation of eNOS. Cardiovasc Res 2007, 73(2):404-413.
52. Feletou M, Vanhoutte PM: EDHF: An update. Clin Sci (Lond) 2009, 117(4):139-155.
53. Ozkor MA, Quyyumi AA: Endothelium-derived hyperpolarizing factor and vascular function. Cardiol Res Pract 2011, 2011:156146.
54. Sandow SL, Tare M, Coleman HA, Hill CE, Parkington HC: Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor. Circ Res 2002, 90(10):1108-1113.
55. Doughty JM, Plane F, Langton PD: Charybdotoxin and apamin block EDHF in rat mesenteric artery if selectively applied to the endothelium. Am J Physiol 1999, 276(3 Pt 2):H1107-H1112.
56. Corriu C, Feletou M, Canet E, Vanhoutte PM: Endothelium-derived factors and hyperpolarization of the carotid artery of the guinea-pig. Br J Pharmacol 1996, 119(5):959-964.
57. Murphy ME, Brayden JE: Apamin-sensitive K + channels mediate an endothelium-dependent hyperpolarization in rabbit mesenteric arteries. J Physiol 1995, 489(Pt 3):723-734.
58. Hannah RM, Dunn KM, Bonev AD, Nelson MT: Endothelial SK(Ca) and IK (Ca) channels regulate brain parenchymal arteriolar diameter and cortical cerebral blood flow. J Cereb Blood Flow Metab 2011, 31(5):1175-1186.
59. Chataigneau T, Feletou M, Duhault J, Vanhoutte PM: Epoxyeicosatrienoic acids, potassium channel blockers and endothelium-dependent hyperpolarization in the guinea-pig carotid artery. Br J Pharmacol 1998, 123(3):574-580.
60. Nelson MT, Quayle JM: Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995, .
61. Neylon CB, Lang RJ, Fu Y, Bobik A, Reinhart PH: Molecular cloning and characterization of the intermediate-conductance Ca(2+)-Activated K(+) channel in vascular smooth muscle: Relationship between K(Ca) channel diversity and smooth muscle cell function. Circ Res 1999, 85(9):e33-e43.
62. Larsen BT, Gutterman DD, Sato A, Toyama K, Campbell WB, Zeldin DC, Manthati VL, Falck JR, Miura H: Hydrogen peroxide inhibits cytochrome p450 epoxygenases: interaction between two endothelium-derived hyperpolarizing factors. Circ Res 2008, 102(1):59-67.
63. Yada T, Shimokawa H, Hiramatsu O, Kajita T, Shigeto F, Goto M, Ogasawara Y, Kajiya F: Hydrogen peroxide, an endogenous endothelium-derived hyperpolarizing factor, plays an important role in coronary autoregulation in vivo. Circulation 2003, 107(7):1040-1045.
64. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A: Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000, 106(12):1521-1530.
65. Morikawa K, Shimokawa H, Matoba T, Kubota H, Akaike T, Talukder MA, Hatanaka M, Fujiki T, Maeda H, Takahashi S, Takeshita A: Pivotal role of Cu, Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest 2003, 112(12):1871-1879.
66. Wynne BM, Labazi H, Tostes RC, Webb RC: Aorta from angiotensin II hypertensive mice exhibit preserved nitroxyl anion mediated relaxation responses. Pharmacol Res 2012, 65(1):41-47.
67. Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, Kemp-Harper BK: A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. Br J Pharmacol 2009, 157(4):540-550.
68. Mustafa AK, Sikka G, Gazi SK, Steppan J, Jung SM, Bhunia AK, Barodka VM, Gazi FK, Barrow RK, Wang R, Amzel LM, Berkowitz DE, Snyder SH: Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ Res 2011, 109(11):1259-1268.
69. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, Takeshita A: The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 1996, 28(5):703-711.
70. Bellien J, Joannides R, Iacob M, Arnaud P, Thuillez C: Evidence for a basal release of a cytochrome-related endothelium-derived hyperpolarizing factor in the radial artery in humans. Am J Physiol Heart Circ Physiol 2006, 290(4):H1347-H1352.
71. Ozkor MA, Murrow JR, Rahman AM, Kavtaradze N, Lin J, Manatunga A, Quyyumi AA: Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. Circulation 2011, 123(20):2244-2253.
72. Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ: Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001, 167(5):2831-2838.
73. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA: Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A 2012, 109(43):17597-17602.
74. Ricciotti E, Yu Y, Grosser T, Fitzgerald GA: COX-2, the dominant source of prostacyclin. Proc Natl Acad Sci U S A 2013, 110(3):E183.
75. Tare M, Parkington HC, Coleman HA: EDHF, NO and a prostanoid: hyperpolarization-dependent and -independent relaxation in guinea-pig arteries. Br J Pharmacol 2000, 130(3):605-618.
76. Dautzenberg M, Just A: Temporal characteristics of nitric oxide-, prostaglandin-, and EDHF-mediated components of endotheliumdependent vasodilation in the kidney. Am J Physiol Regul Integr Comp Physiol 2013, 305(9):R987-R998.
77. Li X, Fang P, Mai J, Choi ET, Wang H, Yang XF: Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol 2013, 6:19.
78. Addabbo F, Montagnani M, Goligorsky MS: Mitochondria and reactive oxygen species. Hypertension 2009, 53(6):885-892.
79. Zhang JG, Nicholls-Grzemski FA, Tirmenstein MA, Fariss MW: Vitamin E succinate protects hepatocytes against the toxic effect of reactive oxygen species generated at mitochondrial complexes I and III by alkylating agents. Chem Biol Interact 2001, 138(3):267-284.
80. Yang B, Rizzo V: TNF-Alpha potentiates protein-Tyrosine nitration through activation of NADPH oxidase and eNOS localized in membrane rafts and caveolae of bovine aortic endothelial cells. Am J Physiol Heart Circ Physiol 2007, 292(2):H954-H962.
81. Cai H: NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res 2005, 96(8):818-822.
82. Houstis N, Rosen ED, Lander ES: Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440(7086):944-948.
83. Mugge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD, Harrison DG: Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 1991, 69(5):1293-1300.
84. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL: Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 1998, 82(12):1298-1305.
85. Langenstroer P, Pieper GM: Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol 1992, 263(1 Pt 2):H257-H265.
86. Oak JH, Cai H: Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007, 56(1):118-126.
87. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, Sack MN, Kastner DL, Siegel RM: Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-Associated periodic syndrome (TRAPS). J Exp Med 2011, 208(3):519-533.
88. David F, Farley J, Huang H, Lavoie JP, Laverty S: Cytokine and chemokine gene expression of IL-1beta stimulated equine articular chondrocytes. Vet Surg 2007, 36(3):221-227.
89. Vlahopoulos S, Boldogh I, Casola A, Brasier AR: Nuclear factor-kappaBdependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: Evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation. Blood 1999, 94(6):1878-1889.
90. Zhang C: The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008, 103(5):398-406.
91. Bagnost T, Berthelot A, Bouhaddi M, Laurant P, Andre C, Guillaume Y, Demougeot C: Treatment with the arginase inhibitor N(omega)-hydroxynor- L-Arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. J Hypertens 2008, 26(6):1110-1118.
92. Demougeot C, Prigent-Tessier A, Marie C, Berthelot A: Arginase inhibition reduces endothelial dysfunction and blood pressure rising in spontaneously hypertensive rats. J Hypertens 2005, 23(5):971-978.
93. Toque HA, Romero MJ, Tostes RC, Shatanawi A, Chandra S, Carneiro ZN, Inscho EW, Webb RC, Caldwell RB, Caldwell RW: p38 Mitogen-Activated protein kinase (MAPK) increases arginase activity and contributes toendothelial dysfunction in corpora cavernosa from angiotensin-II-Treated mice. J Sex Med 2010, 7(12):3857-3867.
94. Satoh M, Fujimoto S, Arakawa S, Yada T, Namikoshi T, Haruna Y, Horike H, Sasaki T, Kashihara N: Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy. Nephrol Dial Transplant 2008, 23(12):3806-3813.
95. Virdis A, Colucci R, Neves MF, Rugani I, Aydinoglu F, Fornai M, Ippolito C, Antonioli L, Duranti E, Solini A, Bernardini N, Blandizzi C, Taddei S: Resistance artery mechanics and composition in angiotensin II-infused mice: Effects of cyclooxygenase-1 inhibition. Eur Heart J 2012, 33(17):2225-2234.
96. Cheng ZJ, Vapaatalo H, Mervaala E: Angiotensin II and vascular inflammation. Med Sci Monit 2005, 11(6):RA194-RA205.
97. Kourembanas S, McQuillan LP, Leung GK, Faller DV: Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993, 92(1):99-104.
98. Wiley KE, Davenport AP: Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system. Br J Pharmacol 2001, 132(1):213-220.
99. Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB: Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 2003, 285(6):L1179-L1183.
100. Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL, Schiffrin EL: Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004, 110(15):2233-2240.
101. Amiri F, Ko EA, Javeshghani D, Reudelhuber TL, Schiffrin EL: Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice. J Hypertens 2010, 28(6):1243-1251.
102. Javeshghani D, Barhoumi T, Idris-Khodja N, Paradis P, Schiffrin EL: Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension 2013, 62(1):112-117.
103. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL: Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colonystimulating factor-deficient mice: Evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol 2005, 25(10):2106-2113.
104. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL: T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011, 57(3):469-476.
105. Bhagat K, Vallance P: Inflammatory cytokines impair endotheliumdependent dilatation in human veins in vivo. Circulation 1997, 96(9):3042-3047.
106. Stenvinkel P: Endothelial dysfunction and inflammation-is there a link? Nephrol Dial Transplant 2001, 16(10):1968-1971.
107. Herder C, Carstensen M, Ouwens DM: Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab 2013, 15(Suppl 3):39-50.
108. Gleissner CA, Zastrow A, Klingenberg R, Kluger MS, Konstandin M, Celik S, Haemmerling S, Shankar V, Giese T, Katus HA, Dengler TJ: IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT3/4 in human vascular endothelial cells. Eur J Immunol 2007, 37(1):177-192.
109. Moore KW, de Waal MR, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
110. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK, Nicoletti A: Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003, 9(1-2):10-17.
111. Gunnett CA, Heistad DD, Faraci FM: Interleukin-10 protects nitric oxidedependent relaxation during diabetes: Role of superoxide. Diabetes 2002, 51(6):1931-1937.
112. Didion SP, Kinzenbaw DA, Schrader LI, Chu Y, Faraci FM: Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension 2009, 54(3):619-624.
113. Oberholzer A, Oberholzer C, Moldawer LL: Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002, 30(1 Supp):S58-S63.
114. Gunnett CA, Heistad DD, Berg DJ, Faraci FM: IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. Am J Physiol Heart Circ Physiol 2000, 279(4):H1555-H1562.
115. Haddad JJ, Fahlman CS: Redox-And oxidant-mediated regulation of interleukin-10: An anti-inflammatory, antioxidant cytokine? Biochem Biophys Res Commun 2002, 297(2):163-176.
116. Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM: Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 2004, 44(1):44-49.
117. Dang PM, Elbim C, Marie JC, Chiandotto M, Gougerot-Pocidalo MA, El- Benna J: Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47PHOX phosphorylation through a decrease in ERK1/2 activity. FASEB J 2006, 20(9):1504-1506.
118. Zemse SM, Hilgers RH, Webb RC: Interleukin-10 counteracts impaired endothelium-dependent relaxation induced by ANG II in murine aortic rings. Am J Physiol Heart Circ Physiol 2007, 292(6):H3103-H3108.
119. Kassan M, Galan M, Partyka M, Trebak M, Matrougui K: Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol 2011, 31(11):2534-2542.
120. Kinzenbaw DA, Chu Y, Pena Silva RA, Didion SP, Faraci FM: Interleukin-10 protects against aging-induced endothelial dysfunction. Physiol Rep 2013, 1(6):e00149.
121. Sikka G, Miller KL, Steppan J, Pandey D, Jung SM, Fraser CD 3rd, Ellis C, Ross D, Vandegaer K, Bedja D, Gabrielson K, Walston JD, Berkowitz DE, Barouch LA: Interleukin 10 knockout frail mice develop cardiac and vascular dysfunction with increased age. Exp Gerontol 2013, 48(2):128-135.
122. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147(11):3815-3822.
123. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A: IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991, 146(10):3444-3451.
124. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10(IL- 10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991, 174(5):1209-1220.
125. Asadullah K, Sterry W, Volk HD: Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003, 55(2):241-269.
126. Csiszar A, Wang M, Lakatta EG, Ungvari Z: Inflammation and endothelial dysfunction during aging: Role of NF-kappaB. J Appl Physiol (1985) 2008, 105(4):1333-1341.
127. Marchesi C, Paradis P, Schiffrin EL: Role of the renin-Angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008, 29(7):367-374.
128. Huang X, Gong R, Li X, Virtue A, Yang F, Yang IH, Tran AH, Yang XF, Wang H: Identification of novel pretranslational regulatory mechanisms for NF-kappaB activation. J Biol Chem 2013, 288(22):15628-15640.
129. Seitz M, Loetscher P, Dewald B, Towbin H, Gallati H, Baggiolini M: Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol 1995, 25(4):1129-1132.
130. Zemse SM, Chiao CW, Hilgers RH, Webb RC: Interleukin-10 inhibits the in vivo and in vitro adverse effects of TNF-Alpha on the endothelium of murine aorta. Am J Physiol Heart Circ Physiol 2010, 299(4):H1160-H1167.
131. Riley JK, Takeda K, Akira S, Schreiber RD: Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem 1999, 274(23):16513-16521.
132. Cattaruzza M, Slodowski W, Stojakovic M, Krzesz R, Hecker M: Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells. J Biol Chem 2003, 278(39):37874-37880.
133. Wehinger J, Gouilleux F, Groner B, Finke J, Mertelsmann R, Weber-Nordt RM: IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett 1996, 394(3):365-370.
134. Finbloom DS, Winestock KD: IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 1995, 155(3):1079-1090.
135. Pattison MJ, Mackenzie KF, Arthur JS: Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J Immunol 2012, 189(6):2784-2792.
136. Jojima T, Suzuki K, Hirama N, Uchida K, Hattori Y: Glimepiride upregulates eNOS activity and inhibits cytokine-induced NF-kappaB activation through a phosphoinoside 3-kinase-Akt-dependent pathway. Diabetes Obes Metab 2009, 11(2):143-149.
137. D'Angelo G, Adam LP: Inhibition of ERK attenuates force development by lowering myosin light chain phosphorylation. Am J Physiol Heart Circ Physiol 2002, 282(2):H602-H610.
138. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD: Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond) 2003, 105(1):45-50.
139. Suttles J, Milhorn DM, Miller RW, Poe JC, Wahl LM, Stout RD: CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action. J Biol Chem 1999, 274(9):5835-5842.
140. Giachini FR, Zemse SM, Carneiro FS, Lima VV, Carneiro ZN, Callera GE, Ergul A, Webb RC, Tostes RC: Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway. Am J Physiol Heart Circ Physiol 2009, 296(2):H489-H496.
141. Noh KT, Son KH, Jung ID, Kang HK, Hwang SA, Lee WS, You JC, Park YM: Protein kinase C delta (PKCdelta)-extracellular signal-regulated kinase 1/2 (ERK1/2) signaling cascade regulates glycogen synthase kinase-3 (GSK-3) inhibition-mediated interleukin-10 (IL-10) expression in lipopolysaccharide (LPS)-induced endotoxemia. J Biol Chem 2012, 287(17):14226-14233.
142. Williams L, Bradley L, Smith A, Foxwell B: Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004, 172(1):567-576.
143. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ: Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002, 169(5):2253-2263.
144. Antoniv TT, Ivashkiv LB: Interleukin-10-induced gene expression and suppressive function are selectively modulated by the PI3K-Akt-GSK3 pathway. Immunology 2011, 132(4):567-577.
145. Pepper MS: Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997, 8(1):21-43.
146. Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol 1990, 6:597-641.
147. Roberts AB: Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 1998, 24(2-3):111-119.
148. Morello JP, Plamondon J, Meyrick B, Hoover R, O'Connor-McCourt MD: Transforming growth factor-beta receptor expression on endothelial cells: heterogeneity of type III receptor expression. J Cell Physiol 1995, 165(1):201-211.
149. Saura M, Zaragoza C, Cao W, Bao C, Rodriguez-Puyol M, Rodriguez-Puyol D, Lowenstein CJ: Smad2 mediates transforming growth factor-beta induction of endothelial nitric oxide synthase expression. Circ Res 2002, 91(9):806-813.
150. Vasquez R, Farias M, Vega JL, Martin RS, Vecchiola A, Casanello P, Sobrevia L: D-glucose stimulation of L-Arginine transport and nitric oxide synthesis results from activation of mitogen-Activated protein kinases p42/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium. J Cell Physiol 2007, 212(3):626-632.
151. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986, 163(5):1037-1050.
152. Saura M, Zaragoza C, Herranz B, Griera M, Diez-Marques L, Rodriguez-Puyol D, Rodriguez-Puyol M: Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells. Circ Res 2005, 97(11):1115-1123.
153. Walshe TE, dela Paz NG, D'Amore PA: The role of shear-induced transforming growth factor-beta signaling in the endothelium. Arterioscler Thromb Vasc Biol 2013, 33(11):2608-2617.
154. Ying WZ, Aaron KJ, Sanders PW: Transforming growth factor-beta regulates endothelial function during high salt intake in rats. Hypertension 2013, 62(5):951-956.
155. Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137-161.
156. Li MO, Wan YY, Flavell RA: T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1-And Th17-cell differentiation. Immunity 2007, 26(5):579-591.
157. Pastrana JL, Sha X, Virtue A, Mai J, Cueto R, Lee IA, Wang H, Yang XF: Regulatory T cells and Atherosclerosis. J Clin Exp Cardiolog 2012, 2012(Suppl 12):2.
158. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA: IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010, 11(11):1014-1022.
159. Miller AM: Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011, 8(1):22.
160. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY: IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205(2):339-346.
161. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY: Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010, 107(5):650-658.
162. Moussion C, Ortega N, Girard JP: The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel 'alarmin'? PLoS One 2008, 3(10):e3331.
163. Grehan JF, Levay-Young BK, Fogelson JL, Francois-Bongarcon V, Benson BA, Dalmasso AP: IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway. J Immunol 2005, 175(3):1903-1910.
164. Dalmasso AP, Goldish D, Benson BA, Tsai AK, Wasiluk KR, Vercellotti GM: Interleukin-4 induces up-regulation of endothelial cell claudin-5 through activation of FoxO1: Role in protection from complement-mediated injury. J Biol Chem 2014, 289(2):838-847.
165. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, Cross R, Sehy D, Blumberg RS, Vignali DA: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450(7169):566-569.
166. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, Wingfield PT, Kim SH, Egwuagu CE: Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med 2014, 20(6):633-641.
167. Shen P, Roch T, Lampropoulou V, O'Connor RA, Stervbo U, Hilgenberg E, Ries S, Dang VD, Jaimes Y, Daridon C, Li R, Jouneau L, Boudinot P, Wilantri S, Sakwa I, Miyazaki Y, Leech MD, McPherson RC, Wirtz S, Neurath M, Hoehlig K, Meinl E, Grützkau A, Grün JR, Horn K, Kühl AA, Dörner T, Bar-Or A, Kaufmann SH, Anderton SM, et al: IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014, 507(7492):366-370.
168. Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, Gutchigian S, Frisch A, Hodge I, Jiang X, Wang H, Yang XF: IL-35 is a novel responsive anti-inflammatory cytokine-A new system of categorizing anti-inflammatory cytokines. PLoS One 2012, 7(3):e33628.
169. Virtue A, Wang H, Yang XF: MicroRNAs and toll-like receptor/interleukin-1 receptor signaling. J Hematol Oncol 2012, 5:66.
170. Virtue A, Mai J, Yin Y, Meng S, Tran T, Jiang X, Wang H, Yang XF: Structural evidence of anti-Atherogenic microRNAs. Front Biosci (Landmark Ed) 2011, 16:3133-3145.
171. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006, 103(33):12481-12486.
172. Bhaumik D, Patil CK, Campisi J: MicroRNAs: An important player in maintaining a balance between inflammation and tumor suppression. Cell Cycle 2009, 8(12):1822.
173. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM, Lindsay MA: Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol 2008, 180(8):5689-5698.
174. Xiao B, Liu Z, Li BS, Tang B, Li W, Guo G, Shi Y, Wang F, Wu Y, Tong WD, Guo H, Mao XH, Zou QM: Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. J Infect Dis 2009, 200(6):916-925.
175. Worm J, Stenvang J, Petri A, Frederiksen KS, Obad S, Elmen J, Hedtjarn M, Straarup EM, Hansen JB, Kauppinen S: Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebpBeta and down-regulation of G-CSF. Nucleic Acids Res 2009, 37(17):5784-5792.
176. Matsui J, Wakabayashi T, Asada M, Yoshimatsu K, Okada M: Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem 2004, 279(18):18600-18607.
177. Suarez Y, Wang C, Manes TD, Pober JS: Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol 2010, 184(1):21-25.
178. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ: MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008, 105(5):1516-1521.
179. Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, Hunninghake GM, Vera MP, Blackwell TS, Baron RM, Feinberg MW: MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest 2012, 122(6):1973-1990.
180. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF: MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A 2010, 107(30):13450-13455.
181. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC: Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 2007, 100(8):1164-1173.
182. Hagiwara S, McClelland A, Kantharidis P: MicroRNA in Diabetic Nephropathy: Renin Angiotensin, AGE/RAGE, and Oxidative Stress Pathway. J Diabetes Res 2013, 2013:173783.
183. Sun HX, Zeng DY, Li RT, Pang RP, Yang H, Hu YL, Zhang Q, Jiang Y, Huang LY, Tang YB, Yan GJ, Zhou JG: Essential role of microRNA-155 in regulating endothelium-dependent vasorelaxation by targeting endothelial nitric oxide synthase. Hypertension 2012, 60(6):1407-1414.
184. Li D, Yang P, Xiong Q, Song X, Yang X, Liu L, Yuan W, Rui YC: MicroRNA- 125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells. J Hypertens 2010, 28(8):1646-1654.